FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Krankenhaus Martha-Maria Halle-Dölau
Hospital
Location:
Halle, Germany (DE)
ISNI
: -
Publications
(7)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2 (2025)
Rittel JC, Hudasch D, Doppler K, Bergh FT, Lesser M, Aktas O, Nagel M, et al.
Journal article
Different pain phenotypes are associated with anti-Caspr2 autoantibodies. (2024)
Greguletz P, Plötz M, Baade-Büttner C, Bien CG, Eisenhut K, Geis C, Handreka R, et al.
Journal article
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis (2022)
Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, et al.
Journal article
Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease (2022)
Grueter T, Moellers FE, Tietz A, Dargvainiene J, Melzer N, Heidbreder A, Strippel C, et al.
Journal article
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis. (2021)
Tietz AK, Angstwurm K, Baumgartner T, Doppler K, Eisenhut K, Elisak M, Franke A, et al.
Journal article
Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment (2019)
Schubert J, Braemer D, Huttner H, Gerner S, Fuhrer H, Melzer N, Dik A, et al.
Journal article
Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017)
Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al.
Conference contribution